As its oncology stalwart Herceptin prepares for a rush of biosimilar competitors, Roche has high hopes for its newer horse in the HER2-positive breast cancer race. And now, Kadcyla’s ready to run in a new indication. More: Roche's breast cancer
read moreIt’s not often that biotech sees a record-breaking IPO, but longtime unicorn and fundraising champ Moderna managed just that last year. And the newly public company’s CEO, Stéphane Bancel, topped the charts himself with a $58.6 million compensation package. More: Riding
read moreAstraZeneca warns of slower China growth after losing out to local generic in a procurement plan. BeiGene chief becomes the second-highest-paid biopharma CEO in 2018. China’s Kangmei Pharma faces potential delisting after a $4.4 billion accounting “error.” And more. More:
read moreWith generics attacking Advair, GlaxoSmithKline has talked up prospects for 3-in-1 respiratory drug Trelegy. Now, the company has data in hand that could help it move into the asthma arena—though it’s not all positive. More: GSK chases Trelegy asthma nod
read moreNovo Nordisk has been fighting head-to-head with Eli Lilly for share in the GLP-1 diabetes market—and losing, as Lilly’s weekly Trulicity stole scripts from Novo’s daily Victoza. But now that Novo has its own weekly GLP-1 drug in Ozempic, the
read moreJohnson & Johnson has fallen behind the Pfizer-Astellas team with Erleada in the drug’s first approved indication. But now the drug looks poised to bring in another—and perhaps sooner than expected. More: J&J eyes prostate cancer boost as FDA accepts
read more© 1994 - 2026 B.M. Pharmaceuticals